MYCN-amplified tumor cells seem to be dependent on VRK1 expression for its exacerbated proliferation, raising the possibility of using VRK1 inhibitors for NB treatment as an alternative to MYCN targeting. This evidence concerns the gene MYCN and neuroblastoma.